Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 13;54(8):752–761. doi: 10.1007/s00535-019-01569-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 2 — SVR12 by baseline patient and disease characteristics. Efficacy of 8-week G/P treatment reported by baseline patient (a) and disease (b) characteristics using an ITT analysis. The dashed line represents the overall SVR12 for 899 patients included in the analysis. ^aAll patients with missing data for baseline polymorphisms achieved SVR12. ^bDefined as having any baseline NS3 resistance-associated variant (at amino acid positions 155, 156, and 168) at ≥ 15% NGS detection threshold. ^cDefined as having any baseline NS5A resistance-associated variant (at amino acid positions 24, 28, 30, 92, and 93) at ≥ 15% NGS detection threshold